Author information
1From the UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
2Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
3Irkutsk AIDS Centre, Irkutsk Regional Centre for the Prevention and Control of AIDS and Infectious Diseases (IOC AIDS), Russia.
4Republican Clinical Hospital of Infectious Diseases, Saint Petersburg, Russia.
5The City HIV Centre, Saint Petersburg, Russia.
6Department of Children's Infectious Diseases, Medical University of Warsaw; Hospital of Infectious Diseases in Warsaw, Poland.
7Pediatric Infectious Diseases, Hospital Gregorio Marañón, IISGM, UCM, CIBERINFEC ISCIII, Madrid, Spain; and.
8Institute for Global Health, University College London, London, United Kingdom.
Abstract
We evaluated the effectiveness and safety of direct-acting antivirals in adolescents with hepatitis C (HCV)/HIV coinfection using pooled individual patient-level data from 5 European cohorts. Of 122 participants in follow-up from November 2013 to August 2021, 19 were treated <18 years of age; of 15 with HCV RNA available at/after 12 weeks post-treatment, all had sustained virologic response with acceptable safety. This evidence addresses an important gap in knowledge of treatment outcomes in adolescents with HCV/HIV coinfection in real-life settings.